Literature DB >> 23359684

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.

Siming Zhao1, Murim Choi, John D Overton, Stefania Bellone, Dana M Roque, Emiliano Cocco, Federica Guzzo, Diana P English, Joyce Varughese, Sara Gasparrini, Ileana Bortolomai, Natalia Buza, Pei Hui, Maysa Abu-Khalaf, Antonella Ravaggi, Eliana Bignotti, Elisabetta Bandiera, Chiara Romani, Paola Todeschini, Renata Tassi, Laura Zanotti, Luisa Carrara, Sergio Pecorelli, Dan-Arin Silasi, Elena Ratner, Masoud Azodi, Peter E Schwartz, Thomas J Rutherford, Amy L Stiegler, Shrikant Mane, Titus J Boggon, Joseph Schlessinger, Richard P Lifton, Alessandro D Santin.   

Abstract

Uterine serous carcinoma (USC) is a biologically aggressive subtype of endometrial cancer. We analyzed the mutational landscape of USC by whole-exome sequencing of 57 cancers, most of which were matched to normal DNA from the same patients. The distribution of the number of protein-altering somatic mutations revealed that 52 USC tumors had fewer than 100 (median 36), whereas 5 had more than 3,000 somatic mutations. The mutations in these latter tumors showed hallmarks of defects in DNA mismatch repair. Among the remainder, we found a significantly increased burden of mutation in 14 genes. In addition to well-known cancer genes (i.e., TP53, PIK3CA, PPP2R1A, KRAS, FBXW7), there were frequent mutations in CHD4/Mi2b, a member of the NuRD-chromatin-remodeling complex, and TAF1, an element of the core TFIID transcriptional machinery. Additionally, somatic copy-number variation was found to play an important role in USC, with 13 copy-number gains and 12 copy-number losses that occurred more often than expected by chance. In addition to loss of TP53, we found frequent deletion of a small segment of chromosome 19 containing MBD3, also a member of the NuRD-chromatin-modification complex, and frequent amplification of chromosome segments containing PIK3CA, ERBB2 (an upstream activator of PIK3CA), and CCNE1 (a target of FBXW7-mediated ubiquitination). These findings identify frequent mutation of DNA damage, chromatin remodeling, cell cycle, and cell proliferation pathways in USC and suggest potential targets for treatment of this lethal variant of endometrial cancer.

Entities:  

Mesh:

Year:  2013        PMID: 23359684      PMCID: PMC3581983          DOI: 10.1073/pnas.1222577110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

Review 1.  Cyclin E in human cancers.

Authors:  R Donnellan; R Chetty
Journal:  FASEB J       Date:  1999-05       Impact factor: 5.191

2.  Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women.

Authors:  S Talbi; A E Hamilton; K C Vo; S Tulac; M T Overgaard; C Dosiou; N Le Shay; C N Nezhat; R Kempson; B A Lessey; N R Nayak; L C Giudice
Journal:  Endocrinology       Date:  2005-11-23       Impact factor: 4.736

3.  A general transcription initiation factor, human transcription factor IID, overexpressed in human lung and breast carcinoma and rapidly induced with serum stimulation.

Authors:  C Wada; K Kasai; T Kameya; H Ohtani
Journal:  Cancer Res       Date:  1992-01-15       Impact factor: 12.701

4.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells.

Authors:  Yardena Samuels; Luis A Diaz; Oleg Schmidt-Kittler; Jordan M Cummins; Laura Delong; Ian Cheong; Carlo Rago; David L Huso; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Cancer Cell       Date:  2005-06       Impact factor: 31.743

Review 5.  Proteins regulating Ras and its relatives.

Authors:  M S Boguski; F McCormick
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

6.  TAF1 histone acetyltransferase activity in Sp1 activation of the cyclin D1 promoter.

Authors:  Traci L Hilton; Yun Li; Elizabeth L Dunphy; Edith H Wang
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

7.  Two pathogenetic types of endometrial carcinoma.

Authors:  J V Bokhman
Journal:  Gynecol Oncol       Date:  1983-02       Impact factor: 5.482

8.  Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma.

Authors:  M Hendrickson; J Ross; P Eifel; A Martinez; R Kempson
Journal:  Am J Surg Pathol       Date:  1982-03       Impact factor: 6.394

9.  Patterns of somatic mutation in human cancer genomes.

Authors:  Christopher Greenman; Philip Stephens; Raffaella Smith; Gillian L Dalgliesh; Christopher Hunter; Graham Bignell; Helen Davies; Jon Teague; Adam Butler; Claire Stevens; Sarah Edkins; Sarah O'Meara; Imre Vastrik; Esther E Schmidt; Tim Avis; Syd Barthorpe; Gurpreet Bhamra; Gemma Buck; Bhudipa Choudhury; Jody Clements; Jennifer Cole; Ed Dicks; Simon Forbes; Kris Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jon Hinton; Andy Jenkinson; David Jones; Andy Menzies; Tatiana Mironenko; Janet Perry; Keiran Raine; Dave Richardson; Rebecca Shepherd; Alexandra Small; Calli Tofts; Jennifer Varian; Tony Webb; Sofie West; Sara Widaa; Andy Yates; Daniel P Cahill; David N Louis; Peter Goldstraw; Andrew G Nicholson; Francis Brasseur; Leendert Looijenga; Barbara L Weber; Yoke-Eng Chiew; Anna DeFazio; Mel F Greaves; Anthony R Green; Peter Campbell; Ewan Birney; Douglas F Easton; Georgia Chenevix-Trench; Min-Han Tan; Sok Kean Khoo; Bin Tean Teh; Siu Tsan Yuen; Suet Yi Leung; Richard Wooster; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2007-03-08       Impact factor: 49.962

10.  Identification of multiple distinct Snf2 subfamilies with conserved structural motifs.

Authors:  Andrew Flaus; David M A Martin; Geoffrey J Barton; Tom Owen-Hughes
Journal:  Nucleic Acids Res       Date:  2006-05-31       Impact factor: 16.971

View more
  135 in total

1.  Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.

Authors:  Yaser R Hussein; Britta Weigelt; Douglas A Levine; J Kenneth Schoolmeester; Linda N Dao; Bonnie L Balzer; Georgia Liles; Beth Karlan; Martin Köbel; Cheng-Han Lee; Robert A Soslow
Journal:  Mod Pathol       Date:  2014-11-14       Impact factor: 7.842

Review 2.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

3.  Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.

Authors:  Stefania Bellone; Jonathan Black; Diana P English; Carlton L Schwab; Salvatore Lopez; Emiliano Cocco; Elena Bonazzoli; Federica Predolini; Francesca Ferrari; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Am J Obstet Gynecol       Date:  2015-08-10       Impact factor: 8.661

4.  Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.

Authors:  Liancheng Zhu; Salvatore Lopez; Stefania Bellone; Jonathan Black; Emiliano Cocco; Tiffany Zigras; Federica Predolini; Elena Bonazzoli; Beatrice Bussi; Zachary Stuhmer; Carlton L Schwab; Diana P English; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin
Journal:  Tumour Biol       Date:  2015-02-11

5.  Germline Genetic Variants and Lung Cancer Survival in African Americans.

Authors:  Carissa C Jones; William S Bush; Dana C Crawford; Angela S Wenzlaff; Ann G Schwartz; John K Wiencke; Margaret R Wrensch; William J Blot; Stephen J Chanock; Eric L Grogan; Melinda C Aldrich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-06-15       Impact factor: 4.254

6.  Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.

Authors:  Stefania Bellone; Floriana Centritto; Jonathan Black; Carlton Schwab; Diana English; Emiliano Cocco; Salvatore Lopez; Elena Bonazzoli; Federica Predolini; Francesca Ferrari; Dan-Arin Silasi; Elena Ratner; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2015-04-27       Impact factor: 5.482

7.  CHD4 mutations promote endometrial cancer stemness by activating TGF-beta signaling.

Authors:  Yang Li; Qingxin Liu; Daniel J McGrail; Hui Dai; Kaiyi Li; Shiaw-Yih Lin
Journal:  Am J Cancer Res       Date:  2018-05-01       Impact factor: 6.166

Review 8.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

9.  Frameshift Mutations in the Mononucleotide Repeats of TAF1 and TAF1L Genes in Gastric and Colorectal Cancers with Regional Heterogeneity.

Authors:  Hye Rim Oh; Chang Hyeok An; Nam Jin Yoo; Sug Hyung Lee
Journal:  Pathol Oncol Res       Date:  2016-08-29       Impact factor: 3.201

10.  Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.

Authors:  Martin Köbel; Bo Meng; Lien N Hoang; Noorah Almadani; Xiaodong Li; Robert A Soslow; C Blake Gilks; Cheng-Han Lee
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.